This undiscovered hot stock is trading below cash...Please Read
NGSX has a great product called Qutenza(Neuropathic pain) which is available on the Market in Europe and USA since mid 2010 .Qutenza sales could reach 300++Million per year .
sNDA submission for HIV-AN indication in 1H 2011.. FDA approval expected in 3Q 2011 .Qutenza has Blockbuster Potential in this new HIV indication .
Upcoming Major Milestones (click link):
sNDA submission in HIV-associated neuropathy to FDA in 1H 2011
Qutenza, which currently has U.S. orphan drug designation and fast track status, may be eligible for six-month priority review.
Asia/Latin America commercial partnership 1H 2011
Price Target: $15+ by year end
Market Cap: 55.6 M
Cash: 57.7 M
Shares Out: 17.7 M
Float : ~ 4 M
Great article // A MUST READ !!!
Stephen Ghiglieri, EVP, COO and CFO, commented, "We are pleased with Qutenza market acceptance to date and continue to believe that our focused approach to the launch will provide the foundation to enable Qutenza to achieve its market potential. Our decision to move forward with the submission of an sNDA for Qutenza in HIV-AN is a positive step towards potential Qutenza label expansion that, if approved, could significantly expand Qutenza's addressable market. Re-entering the clinic with a Phase 2 study with NGX-1998 is also a significant step forward for this promising product candidate."
Clinical Pipeline Update:
Following a recent meeting with the U.S. Food and Drug Administration (FDA), NeurogesX announced plans to submit a supplemental new drug application (sNDA) for Qutenza in the first half of 2011 for the treatment of HIV-associated neuropathy (HIV-AN) also known as HIV–distal sensory polyneuropathy (HIV-DSP). The sNDA is excepted to be submitted with data from two completed Phase 3 studies in patients with HIV-AN. Qutenza, which currently has U.S. orphan drug designation and fast track status, may be eligible for six-month priority review.